Shimizu Dai, Kanda Mitsuro, Nomoto Shuji, Oya Hisaharu, Takami Hideki, Hibino Soki, Suenaga Masaya, Inokawa Yoshikuni, Hishida Mitsuhiro, Takano Nao, Nishikawa Yoko, Yamada Suguru, Fujii Tsutomu, Nakayama Goro, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Kodera Yasuhiro
Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.
Oncol Rep. 2014 Mar;31(3):1305-13. doi: 10.3892/or.2013.2939. Epub 2013 Dec 20.
Patients with hepatocellular carcinoma (HCC) have a poor prognosis, and novel molecular targets for treating recurrence and progression of the disease along with associated biomarkers are urgently required. In the present study, expression and the regulatory mechanism of TUSC1 (tumor suppressor candidate 1) were investigated to determine if it is a candidate tumor suppressor gene for HCC, which shows repressed transcription that involves aberrant DNA methylation. TUSC1 mRNA expression levels in HCC cell lines and 94 pairs of surgical specimens were determined using quantitative real-time reverse transcription polymerase chain reaction assay. Methylation status of HCC cell lines and clinical samples were analyzed to investigate the regulatory mechanism of TUSC1 transcription and the relationship between the methylation status of the TUSC1 gene and clinicopathological factors. The expression and distribution of the TUSC1 protein in liver tissues were determined using immunohistochemistry. A majority of HCC cell lines (89%) and surgical specimens (84%) demonstrated reduced expression levels of TUSC1 mRNA compared with paired non-cancerous liver tissues. The mean mRNA expression level in HCC was significantly lower than in corresponding non-cancerous liver. In contrast, no significant difference was found in TUSC1 mRNA expression level between adjacent normal and cirrhotic liver tissue from HCC patients. The TUSC1 protein expression pattern in HCC and liver tissues was consistent with TUSC1 mRNA expression. Twenty-nine (31%) of 94 patients showed intragenic hypermethylation of the TUSC1 gene in HCC, and hypermethylation was significantly associated with advanced pathological stage. Subsequently, patients with hypermethylation of the TUSC1 gene had a significantly poorer prognosis than patients without hypermethylation. Our results suggest that TUSC1 is a candidate tumor suppressor gene and intragenic hypermethylation is one of the suppressive mechanisms that regulate TUSC1 transcription in HCC. Intragenic methylation of the TUSC1 gene may serve as a novel prognostic marker of HCC.
肝细胞癌(HCC)患者预后较差,迫切需要用于治疗该疾病复发和进展的新型分子靶点以及相关生物标志物。在本研究中,对TUSC1(肿瘤抑制候选基因1)的表达及其调控机制进行了研究,以确定它是否为HCC的候选肿瘤抑制基因,该基因显示出转录受抑制,这涉及异常的DNA甲基化。使用定量实时逆转录聚合酶链反应分析法测定了HCC细胞系和94对手术标本中TUSC1 mRNA的表达水平。分析了HCC细胞系和临床样本的甲基化状态,以研究TUSC1转录的调控机制以及TUSC1基因甲基化状态与临床病理因素之间的关系。使用免疫组织化学法测定了TUSC1蛋白在肝组织中的表达和分布。与配对的非癌性肝组织相比,大多数HCC细胞系(89%)和手术标本(84%)显示TUSC1 mRNA表达水平降低。HCC中的平均mRNA表达水平显著低于相应的非癌性肝组织。相比之下,HCC患者相邻的正常肝组织和肝硬化肝组织之间的TUSC1 mRNA表达水平没有显著差异。HCC和肝组织中TUSC1蛋白的表达模式与TUSC1 mRNA表达一致。94例患者中有29例(31%)在HCC中显示TUSC1基因的基因内高甲基化,且高甲基化与晚期病理分期显著相关。随后,TUSC1基因高甲基化的患者预后明显比未发生高甲基化的患者差。我们的结果表明,TUSC1是候选肿瘤抑制基因,基因内高甲基化是调节HCC中TUSC1转录的抑制机制之一。TUSC1基因的基因内甲基化可能作为HCC的一种新型预后标志物。